NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PHIO

Phio Pharmaceuticals Corp

Jun 30 • 04:00PM ET

2.35

Dollar change +0.18
Percentage change 8.29	%

Healthcare • Biotechnology • USA • NASD

Peers: GTBP AEON DRMA BCLI BTAI SNGX ALZN QNRX REGN VRTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.51	Insider Own	1.38%	Shs Outstand	4.78M	Perf Week	7.80%
Market Cap	11.27M	Forward P/E	-	EPS next Y	-0.83	Insider Trans	23.74%	Shs Float	4.73M	Perf Month	15.20%
Enterprise Value	-2.01M	PEG	-	EPS next Q	-0.36	Inst Own	3.99%	Short Float	5.09%	Perf Quarter	82.17%
Income	-6.76M	P/S	-	EPS this Y	82.60%	Inst Trans	20.87%	Short Ratio	0.07	Perf Half Y	6.82%
Sales	0.00M	P/B	0.92	EPS next Y	47.47%	ROA	-66.67%	Short Interest	0.24M	Perf YTD	30.56%
Book/sh	2.55	P/C	0.85	EPS next 5Y	64.39%	ROE	-76.12%	52W High	9.79 -76.00%	Perf Year	-62.71%
Cash/sh	2.77	P/FCF	-	EPS past 3/5Y	56.70% 66.30%	ROIC	-55.59%	52W Low	0.97 143.35%	Perf 3Y	-96.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.50% 9.60%	Perf 5Y	-99.15%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	79.86%	Oper. Margin	-	ATR (14)	0.20	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	10.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	54.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.58	EPS Q/Q	90.30%	SMA20	-0.01%	Beta	0.88	Target Price	14.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	10.38%	Rel Volume	0.05	Prev Close	2.17
Employees	5	LT Debt/Eq	0.00	Earnings	May 15 AMC	SMA200	2.72%	Avg Volume	3.30M	Price	2.35
IPO	May 10, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	168,794	Change	8.29%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-25	Resumed	H.C. Wainwright	Buy	$14
Aug-05-20	Initiated	H.C. Wainwright	Buy	$4

Jun-25-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort (Newsfile)
Jun-24-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jun-06-25 07:45AM	Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio (Newsfile) +20.33%
May-28-25 09:02AM	Best Value Stocks to Buy for May 28th (Zacks) +16.96%
04:37AM	New Strong Buy Stocks for May 28th (Zacks)
08:00AM	Loading…
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-19-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference (Newsfile)
May-15-25 04:15PM	Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Newsfile)
May-07-25 07:45AM	Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial (Newsfile) +18.60%
May-01-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Apr-23-25 10:15AM	Best Momentum Stocks to Buy for April 23rd (Zacks) -18.73%
06:45AM	Best Value Stocks to Buy for April 23rd (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks) +7.14%
Apr-09-25 07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort (Newsfile) +52.48%
Apr-03-25 07:45AM	Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 (Newsfile)
04:00PM	Loading…
Mar-31-25 04:00PM	Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update (Newsfile) -5.38%
Mar-10-25 07:45AM	American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting (Newsfile)
Mar-05-25 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study (Newsfile) +5.30%
Feb-26-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Feb-20-25 07:45AM	Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors (Newsfile)
Feb-03-25 07:45AM	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Jan-22-25 07:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.66%
Jan-21-25 11:15AM	Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -10.47%
Jan-16-25 01:00PM	Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +9.40%
Jan-15-25 07:00AM	Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -25.70%
Jan-14-25 07:00AM	Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -45.76%
Jan-13-25 12:45PM	Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why (Benzinga) +290.53%
07:45AM	Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762 (Newsfile)
Jan-02-25 07:45AM	Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology (Newsfile) +5.56%
Dec-23-24 01:15PM	Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) +26.70%
02:28PM	Loading…
Dec-19-24 02:28PM	Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (Newsfile) -30.68%
07:45AM	Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 (Newsfile)
Dec-12-24 09:21AM	Phio Pharmaceuticals Announces Publication in Frontiers in Immunology (Newsfile) +6.34%
Dec-10-24 07:45AM	Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award (Newsfile)
Dec-03-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Nov-19-24 07:45AM	Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study (Newsfile) +12.42%
Nov-14-24 05:47PM	Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Newsfile) -5.11%
Nov-07-24 10:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Nov-01-24 07:45AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile)
Oct-24-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Newsfile)
Oct-18-24 01:30PM	Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +9.81%
08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series (Newsfile)
Oct-16-24 08:00AM	Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference (Newsfile) +17.75%
Oct-07-24 08:00AM	Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells (Newsfile) -6.17%
Oct-02-24 04:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -6.47%
Oct-01-24 08:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference (Newsfile)
Sep-25-24 08:00AM	INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society (Newsfile)
Sep-17-24 08:00AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) +11.64%
Sep-16-24 08:00AM	Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA (Newsfile)
Sep-09-24 07:00AM	Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Newsfile) +6.13%
Aug-29-24 08:30AM	Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series (Newsfile) -7.37%
Aug-14-24 05:00PM	Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Aug-06-24 08:00AM	Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound (Newsfile)
Aug-01-24 08:00AM	Phio Pharmaceuticals Announces New Chief Financial Officer (Newsfile) -7.34%
Jul-12-24 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds (Newsfile) -13.60%
Jul-08-24 08:00AM	Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762 (Newsfile) +9.06%
Jul-05-24 08:00AM	Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds (Newsfile)
Jul-02-24 11:45AM	Phio Pharmaceuticals Announces Reverse Stock Split (Newsfile) -9.17%
Jun-18-24 07:30AM	Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging (Newsfile)
May-28-24 07:30AM	Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762 (Newsfile)
May-23-24 05:00PM	Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Newsfile)
May-17-24 09:00AM	Phio Pharmaceuticals Secures New Investor (GlobeNewswire) +7.44%
May-16-24 08:00AM	Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) (GlobeNewswire) -8.45%
May-15-24 01:00PM	Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study (GlobeNewswire) +9.02%
May-09-24 11:53PM	PHIO Stock Earnings: Phio Pharma Reported Results for Q1 2024 (InvestorPlace) -8.51%
05:25PM	Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update (GlobeNewswire)
Apr-30-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) (GlobeNewswire)
Apr-22-24 01:10PM	Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells (GlobeNewswire) +29.69%
Apr-16-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID) (GlobeNewswire)
Apr-11-24 07:30AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) (GlobeNewswire)
Apr-03-24 07:30AM	National Spotlight Features Phio's Innovative RNAi Technology Platform (GlobeNewswire)
Apr-02-24 07:30AM	Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update (GlobeNewswire)
Mar-21-24 07:30AM	Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire) -21.50%
Mar-13-24 02:00PM	Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research (GlobeNewswire)
Mar-06-24 10:30AM	Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders (GlobeNewswire) +6.63%
Jan-31-24 08:00AM	Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies (GlobeNewswire)
Dec-07-23 08:00AM	Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds (GlobeNewswire) -42.14%
Nov-09-23 04:30PM	Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -10.53% +5.88%
07:30AM	Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas (GlobeNewswire)
Nov-03-23 12:00PM	Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control (GlobeNewswire) +6.57%
Oct-12-23 11:00AM	Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -32.31%
Oct-11-23 07:30AM	Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894 (GlobeNewswire) +87.05%
Sep-06-23 07:30AM	Phio CEO to Speak at Wainwright Conference in New York in September (GlobeNewswire)
Aug-21-23 07:30AM	Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute (GlobeNewswire)
Aug-10-23 04:30PM	Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jun-02-23 01:30PM	Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire)
May-31-23 08:00AM	Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) -13.15%
May-24-23 07:30AM	Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute (PR Newswire)
May-18-23 12:00PM	Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells (PR Newswire) +34.31%
May-16-23 07:30AM	Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas (PR Newswire) +21.36%
May-11-23 05:00PM	Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (PR Newswire) -10.14%
Apr-20-23 02:20PM	Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Apr-18-23 12:10PM	Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -19.24%
07:30AM	Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL (PR Newswire)
Apr-17-23 07:30AM	Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity (PR Newswire) +18.48%
Mar-22-23 05:05PM	Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update (PR Newswire) +8.22%
Feb-22-23 07:30AM	Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer (PR Newswire)
Feb-13-23 07:30AM	Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements (PR Newswire)
Feb-10-23 07:30AM	Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification (PR Newswire) -11.68%
Jan-25-23 08:30AM	Phio Pharmaceuticals Announces Reverse Stock Split (PR Newswire) -6.45%

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bitterman Robert J	Chairman, Pres & CEO	Jun 10 '25	Buy	2.42	2,000	4,840	27,149	Jun 11 05:00 PM
Ferrara Robert L	Director	Jun 10 '25	Buy	2.42	2,500	6,050	15,666	Jun 11 04:59 PM
Bitterman Robert J	Chairman, Pres & CEO	Jun 09 '25	Buy	2.75	1,500	4,125	25,149	Jun 10 04:43 PM
Bitterman Robert J	Chairman, Pres & CEO	May 21 '25	Buy	1.77	3,000	5,310	22,449	May 23 09:04 AM
Bitterman Robert J	Chairman, Pres & CEO	May 22 '25	Buy	1.78	1,200	2,136	23,649	May 23 09:04 AM
Ferrara Robert L	Director	May 20 '25	Buy	1.82	2,500	4,550	13,166	May 21 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHIO

Phio Pharmaceuticals Corp

Upgrade your FINVIZ experience